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SUMMARY – The effectiveness of homocysteine-lowering therapy on stroke prevention is still 
unclear. Although randomized controlled epidemiological trials have yielded mixed findings, a mul-
ticenter trial did not show any beneficial effect. Genetic studies are still lacking. Therefore, we report 
on a female patient with transient ischemic attacks and the thermolabile variant of methylenetetra-
hydrofolate reductase (TT genotype), who benefited from supplemental therapy for homocysteine 
lowering.
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Introduction
Over the last decade, following in vitro and in vivo 
observations of a homocysteine-associated vascular 
pathology, convincing epidemiological evidence has 
been gathered on the relation between moderate el-
evation of plasma homocysteine (Hcy) and vascular 
disease, including cerebral ischemia1. On the other 
hand, randomized controlled epidemiological trials 
have yielded mixed findings regarding the effective-
ness of therapeutic Hcy lowering on stroke preven-
tion. Furthermore, a large multicenter trial has shown 
that folic acid supplementation, despite Hcy lowering, 
does not demonstrate a major effect in averting stroke2. 
However, increased plasma Hcy due to a mutation in 
the methylenetetrahydrofolate reductase (MTHFR) 
gene is associated with a procoagulative state as well 
as accelerated atherosclerosis, independently of other 
risk factors. Therefore, in certain patients with ce-
rebral ischemic events, supplemental therapy with 
a Hcy-lowering strategy could be beneficial. In this 
context, we present a case of a young woman with the 
thermolabile variant of MTHFR (TT genotype) in 
association with low serum vitamin B12 who suffered 
multiple transient ischemic attacks (TIAs).
Case Report
A 40-year-old Caucasian right-handed female was 
admitted to the Department of Vascular Neurology 
and Neurological Intensive Care, University Medical 
Center in Ljubljana, Slovenia, in the fall of 2008, for 
a detailed diagnostic work-up to establish the etiol-
ogy of several TIAs in the previous six months. TIAs 
had presented as temporary dysarthria with paresis of 
the right corner of her mouth and mild right-sided 
hemiparesis with no weakness, paresthesias or clum-
siness of any of her limbs. Her symptoms lasted from 
a couple of minutes to 90 minutes and resolved spon-
taneously with no permanent deficit. Her medical 
therapy on admission consisted of extended-release 
dipyridamole with acetylsalicylic acid, and a thyrox-
ine analogue for hypothyroidism due to autoimmune 
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thyroid disease. At the age of 13, she was diagnosed 
with Henoch-Schönlein purpura with skin and renal 
involvement, and at the age of 29 she developed acute 
myeloblastic leukemia, which was successfully treated 
with chemotherapy and irradiation. Her mother had 
suffered multiple ischemic cerebrovascular strokes due 
to patent foramen ovale and her father had an isch-
emic cerebrovascular stroke at the age of 70. On ad-
mission, the patient was cognitively intact, euphasic, 
and no slurred speech was observed. Examination of 
the cranial nerves was normal, meningeal signs were 
not present, and no murmurs were heard over the 
neck arteries. Further neurologic examination did not 
reveal any abnormality in muscle bulk, muscle tone, 
muscle strength or tendon jerks. There were no signs 
of incoordination, clumsiness or pronator drift. Sen-
sory testing, including vibration and position sense, 
was normal, as were her stance and gait. Cardiac, pul-
monary and abdominal examinations were normal. 
There was no rash. Computed tomography (CT) scan 
performed shortly after the first TIA attack revealed 
no abnormalities. Transthoracic cardiac echosonogra-
phy was normal. Twenty-four-hour ECG monitoring 
revealed sinus rhythm with no significant paroxysmal 
rhythm disturbances, while blood pressure values were 
in the upper normal range throughout twenty-four-
hour monitoring. During her hospital stay at our de-
partment, magnetic resonance (MR) scan of the head 
combined with MR angiography of the cerebral arter-
ies and angiosonography of the cervical arteries showed 
no abnormalities. Transcranial Doppler (TCD) with 
the Valsalva maneuver showed no signs of right-to-left 
shunt. Transesophageal cardiac echosonography using 
contrast medium revealed a normally-shaped interatrial 
septum with a closed foramen ovale. Blood lipids, blood 
glucose and tests of hemostasis were all normal, inborn 
hypercoagulability disorders (such as factor V Leiden 
variant, prothrombin 20210G>A mutation) were ex-
cluded and no significant elevations of anticardiolipin 
antibodies or lupus anticoagulant were detected. Dur-
ing her stay at Neurology Department, no further neu-
rologic deficits occurred. On discharge, her neurologic 
examination was completely normal. She continued 
antiplatelet therapy (dipyridamole and acetylsalicylic 
acid) and treatment with a thyroxine analogue. 
At the beginning of 2009, she was also seen by 
a rheumatologist for further rheumatologic work-up. 
Additional laboratory tests performed at her first visit 
revealed only mild erythrouria, while serologic tests 
showed a low titer of IgG anticardiolipin antibodies 
and transient IgA anti-beta 2 glycoprotein I antibod-
ies. Their values did not suffice to support the diagno-
sis of the antiphospholipid syndrome. She continued 
with her antiplatelet therapy, but despite regular treat-
ment she experienced two additional TIAs in the fol-
lowing months, both of which resolved spontaneously. 
The neurologist who suspected Hashimoto’s enceph-
alopathy (further thyroid testing revealed a euthyroid 
state and a high titer of anti-thyroglobulin antibodies) 
replaced the combination of extended-release dipyri-
damole and acetylsalicylic acid with a combination 
of acetylsalicylic acid and clopidogrel. In the light of 
the previous negative tests for thrombophilia and an-
tiphospholipid antibodies, the patient was additional-
ly tested for Hcy, which was found to be elevated (20.9 
µmol/L). Supplementation therapy with folic acid and 
other B vitamins (vitamin B6, thiamine, riboflavin, 
niacin and pantothenic acid) and with the addition of 
vitamin B12, after confirmation of hypovitaminosis 
B12 (with no antibodies against intrinsic factor), was 
started immediately. Additional genetic testing con-
firmed homozygosity for the thermolabile variant of 
MTHFR (TT genotype). After a month of supple-
mentation treatment, her Hcy level was in the normal 
range. Soon after starting replacement therapy, the 
patient also reported a considerably improved state of 
health. She continued to receive combined antiplatelet 
therapy and vitamin supplementation and suffered no 
TIAs in the next two years of follow-up.
Discussion
Moderate to intermediate elevations of the plasma 
Hcy concentration, occurring in 5%-7% of the popu-
lation, are recognized as a risk factor for premature 
cerebro- and cardiovascular disease3,4. These elevated 
plasma Hcy levels are due to various genetic defects 
(such as polymorphisms in the MTHFR gene)5, vi-
tamin deficiencies (vitamin B6, vitamin B12 and folic 
acid, necessary vitamin cofactors), renal impairment 
(the kidneys perform up to 70% of the clearance of 
Hcy), various drugs (antiepileptic drugs, methotrex-
ate, theophylline, nicotinic acid, fibrates, levodopa, 
metformin)6, hypothyroidism, hyperproliferative dis-
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orders (such as certain cancers, psoriasis), sickle-cell 
anemia, increasing age, high protein intake and low 
intake of vegetables or fruit7.
Elevated plasma Hcy is a strong, graded, indepen-
dent risk factor for various vascular events including 
stroke, recurrent stroke and silent brain infarct8,9. In 
the Rotterdam study, it was estimated that each 1 
µmol/L increase in plasma Hcy concentration was as-
sociated with a 6%-7% increase in the risk of stroke10. 
In the Physicians’ Health Study, a slight increase (1.4-
fold) in the risk of stroke was observed in subjects with 
plasma Hcy >12.7 µmol/L compared to subjects with 
Hcy concentrations below this value11. Several stud-
ies have suggested that hyperhomocysteinemia is also 
a risk factor for small vessel cerebrovascular disease, 
resulting in cerebral white matter hyperintensities on 
magnetic resonance imaging and development of cog-
nitive impairment and dementia12,13. 
Due to the dependence of Hcy metabolism on 
folate, vitamin B12 and vitamin B6, it was expected 
that the administration of these vitamins could re-
duce plasma Hcy levels. According to previous tri-
als, vitamin therapy reduces total Hcy14, and reverses 
endothelial dysfunction induced by high total Hcy15. 
However, it is still unclear whether vitamin supple-
mentation prevents vascular events such as stroke and/
or silent brain infarct. 
The Vitamin Intervention for Stroke Prevention 
(VISP) trial originally did not show the efficacy of 
combined high-dose vitamin therapy for recurrent 
vascular events in patients with previous nondisabling 
stroke2. However, after exclusion of patients with vi-
tamin B12 malabsorption, those who had received 
parenteral vitamin B12 and other vitamin B12 supple-
ments and those with renal failure from the original 
VISP patient group, the stroke incidence was statis-
tically significantly lowered by treatment with high-
dose vitamin therapy16. Other reports also show the 
beneficial effect of vitamin supplementation therapy 
on stroke risk reduction, including the Heart Out-
comes Prevention Evaluation 2 (HOPE-2) study17 
and a meta-analysis of eight relevant randomized tri-
als reported by Wang et al.18.
Despite these initial convincing data, they were 
not confirmed by later studies. Lee et al.19 published 
a meta-analysis of thirteen randomized controlled tri-
als that included participants receiving therapy with 
folic acid to decrease plasma Hcy levels. Folic acid 
supplementation did not demonstrate any major effect 
on averting stroke among persons with high cardio-
vascular risk. Similarly, in a recent meta-analysis of 
eight randomized vitamin treatment trials, Clarke et 
al.20 found no significant effects of dietary supplemen-
tation with folic acid on stroke and other cardiovas-
cular events. In the Study of the Effectiveness of Ad-
ditional Reductions in Cholesterol and Homocysteine 
(SEARCH), reductions in blood Hcy levels with folic 
acid and vitamin B12 supplementation in patients af-
ter myocardial infarction did not show any beneficial 
effects on further major vascular events21. Despite the 
suggestion that such treatment might preferentially 
reduce stroke17,18, SEARCH found no significant ef-
fect of vitamin therapy on stroke reduction21.  
In summary, hyperhomocysteinemia is recognized 
as an independent risk factor for cerebrovascular dis-
ease4. However, according to the results of recent stud-
ies, vitamin supplementation has no beneficial effect 
on secondary prevention of cerebrovascular disease. 
At present, screening for hyperhomocysteinemia and 
vitamin therapy is therefore not recommended. In our 
young patient with no other well-known cardiovas-
cular risk factors (smoking, hyperlipidemia, arterial 
hypertension or diabetes mellitus), different types of 
thrombophilia (including factor V Leiden, mutation 
in the prothrombin gene, antiphospholipid syndrome) 
and structural diseases of the heart and vessels were 
all excluded. Since she suffered further TIAs despite 
appropriate antiplatelet therapy, it was also decided to 
test her for hyperhomocysteinemia, which was con-
firmed and found to be caused by homozygosity for 
the thermolabile variant of MTHFR (TT genotype) 
in association with low serum vitamin B12 (possibly 
due to irradiation of the stomach region during leuke-
mia treatment). After starting vitamin supplementa-
tion therapy, the patient had no further TIA episodes 
in the next two years of follow-up. Vitamin supple-
mentation therapy was beneficial, with an evident 
clinical response. Despite the present diagnostic and 
treatment recommendations for secondary preven-
tion, we believe that Hcy lowering could be beneficial 
in some patients with cerebrovascular disease, as, for 
example, in younger patients with no additional well-
known cardiovascular risk factors or in the very early 
stages of vascular disease elaboration. Further studies 
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should attempt to clearly define which patients might 
benefit from screening for hyperhomocysteinemia and 
subsequent vitamin supplementation therapy.
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Sažetak
USPJEŠNO LIJEČENJE MOŽDANE ISHEMIJE DODACIMA HRANI U BOLESNICE 
S HIPERHOMOCISTEINEMIJOM
M. Zaletel, A. Ambrožič, N. Gašperšič, M. Zupan i B. Žvan
Učinkovitost terapije snižavanja homocisteina u prevenciji moždanog udara ostaje nejasnom. Iako su randomizirana 
kontrolirana epidemiološka ispitivanja polučila mješovite nalaze, jedna multicentrična studija nije pokazala nikakav kori-
stan učinak, dok genetičke studije još uvijek nedostaju. Prikazuje se slučaj bolesnice s prolaznim ishemijskim napadajima 
i termolabilnom varijantom metilen-tetrahidrofolat reduktaze (TT genotip) u koje se terapija dodacima hrani radi sniža-
vanja homocisteina pokazala korisnom.  
Ključne riječi: Hiperhomocisteinemija; Ishemijski napadaj, prolazni; Metilen-tetrahidrofolat  reduktaza; Vitamini; Dodaci 
hrani

